Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

About

LEADERSHIP

OUR TEAM

BOARD OF DIRECTORS

INVESTORS

Selective Targeting of Highly Cytotoxic T Cells in Autoimmune Diseases

Abcuro is developing its lead product candidate ABC008 for autoimmune disorders and rare cancers, including inclusion body myositis (IBM), T Cell Large Granular Lymphocytic Leukemia (T-LGLL) and T and NK cell lymphomas. ABC008 is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting killer cell lectin-like receptor G1 (KLRG1), a marker selectively expressed on these highly cytotoxic T cells.

In IBM and T-LGLL, cytotoxic T cells are a major source of chronic tissue damage. For mature T and NK cell lymphomas, the KLRG1 expressing T cells or NK cells are malignant.  In November 2021, we presented initial results from a Phase 1 open-label trial of ABC008 in IBM at American College of Rheumatology Convergence 2021 (view poster) and an updated dataset was presented at GCOM 2022 (view poster). In this trial, ABC008 demonstrated potent depletion of KLRG1+ T cells in patients with IBM.

View Pipeline

Martin, Alex

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

 READ MORE

Alex Martin

Chief Executive Officer

x

Alex Martin

Chief Executive Officer

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

Wilkins, Jeffrey

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

 READ MORE

H. Jeffrey Wilkins, MD

Chief Medical Officer

x

H. Jeffrey Wilkins, MD

Chief Medical Officer

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.

Tubridy, Karen

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics.  Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.  She has had responsibility for driving global program strategies to IND,

 READ MORE

Karen Tubridy, PharmD

Chief Operating Officer

x

Karen Tubridy, PharmD

Chief Operating Officer

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics.  Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.  She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings.  In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen).  She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs.  Karen holds a BS in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.

Amador, Stephanie

Stephanie Amador

Senior Manager,
CMC Project Management

x

Stephanie Amador

Senior Manager,
CMC Project Management

Borbas, Dave

Dave Borbas

Research VP,
Head of Data Management

x

Dave Borbas

Research VP,
Head of Data Management

Bowers, Charlotte

Charlotte Bowers

Senior Manager, Quality Control

x

Charlotte Bowers

Senior Manager, Quality Control

Brennan, Eileen

Eileen Brennan

Senior Manager, Regulatory Affairs

x

Eileen Brennan

Senior Manager, Regulatory Affairs

Byrne, Donna

Donna Byrne

Director, Clinical Operations

x

Donna Byrne

Director, Clinical Operations

Chaney, Terry

Terry Chaney

Associate Director,
GMP QA Operations

x

Terry Chaney

Associate Director,
GMP QA Operations

Chartienitz, Brett

Brett Chartienitz

IT Operations Manager

x

Brett Chartienitz

IT Operations Manager

Chen, Weilee

Weilee Chen

Senior Manager,
CMC Downstream Manufacturing

x

Weilee Chen

Senior Manager,
CMC Downstream Manufacturing

Cooper, Ken

Ken Cooper

Clinical Operations, Trial Management

x

Ken Cooper

Clinical Operations, Trial Management

Duymich, Christopher

Christopher Duymich

Director, CMC Project Management

x

Christopher Duymich

Director, CMC Project Management

Geary, Jeff

Jeff Geary

Director, Human Resources

x

Jeff Geary

Director, Human Resources

Greenberg, Steven A.

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and the Chief Scientific Advisor. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics,

 READ MORE

Steven A. Greenberg, MD

Chief Scientific Advisor & Co-Founder

x

Steven A. Greenberg, MD

Chief Scientific Advisor & Co-Founder

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and the Chief Scientific Advisor. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics, including co-inventing a therapeutic monoclonal antibody for dermatomyositis currently in late-stage clinical trials. He has authored over 100 publications and served as Principal Investigator for multiple clinical trials. Steve received an A.B. degree in Mathematics from Princeton University, an M.S. degree in Medical Informatics from Massachusetts Institute of Technology, and an M.D. degree from Harvard Medical School through the Harvard-MIT Health Science and Technology Program.

Gress, Mike

Mike Gress

VP, Clinical Development,
Head of Clinical Trial Management

x

Mike Gress

VP, Clinical Development,
Head of Clinical Trial Management

Han Fang

Fang Han

Director, Financial Planning & Analysis

x

Fang Han

Director, Financial Planning & Analysis

Hoffer, LaDonna

LaDonna Hoffer

Project Manager

x

LaDonna Hoffer

Project Manager

Houts, Ian

Ian Houts

Senior Director, Supply Chain

x

Ian Houts

Senior Director, Supply Chain

Hwang, Ella

Ella Hwang

Vice President, Quality

x

Ella Hwang

Vice President, Quality

Jiang, Lusi

Lusi Jiang

Accounting Manager

x

Lusi Jiang

Accounting Manager

LeMessurier, Hugo

Hugo LeMessurier

Director, Abcuro Pty Ltd

x

Hugo LeMessurier

Director, Abcuro Pty Ltd

Lewis, Samantha

Samantha Lewis

Associate Director,
CMC Supply Chain and Logistics

x

Samantha Lewis

Associate Director,
CMC Supply Chain and Logistics

Loi, Chris

Christopher Loi

Associate Director, QA
Compliance & Training

x

Christopher Loi

Associate Director, QA
Compliance & Training

Luk, Jeffrey

Jeffrey Luk

Director, Head of Manufacturing

x

Jeffrey Luk

Director, Head of Manufacturing

Lurk, Kristin

Kristin Lurk

Senior Director
Program Management

x

Kristin Lurk

Senior Director
Program Management

Mansuri, Daniel

Daniel Mansuri

Head of Corporate Development

x

Daniel Mansuri

Head of Corporate Development

Marth, Andrew

Andrew Marth

Director, Quality Control

x

Andrew Marth

Director, Quality Control

Martin, Alex

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

 READ MORE

Alex Martin

Chief Executive Officer

x

Alex Martin

Chief Executive Officer

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

McClain, Michael

Michael McClain

Associate Director, Clinical Operations

x

Michael McClain

Associate Director, Clinical Operations

Morgan, Shelly

Shelly Morgan

Director, Regulatory Affairs

x

Shelly Morgan

Director, Regulatory Affairs

Motschwiller, Ricky

Richard Motschwiller

VP, Finance

x

Richard Motschwiller

VP, Finance

Neely, Mike

Mike Neely

Senior Manager,
CMC Drug Product Manufacturing

x

Mike Neely

Senior Manager,
CMC Drug Product Manufacturing

Nguyen, Charlie

Charlie Nguyen

Senior Manager, CMC Process Development

x

Charlie Nguyen

Senior Manager, CMC Process Development

Obi, Chidi

Chidi Obi

Director, Analytical Development

x

Chidi Obi

Director, Analytical Development

Orozco, Raquel

Raquel Orozco

Director, CMC
Process Development

x

Raquel Orozco

Director, CMC
Process Development

Patel, Zarna

Zarna Patel

Director, Quality Systems

x

Zarna Patel

Director, Quality Systems

Peabody, Lynn

Lynn Peabody

Associate Director,
Analytical Development

x

Lynn Peabody

Associate Director,
Analytical Development

Pepen, Johnny

Johnny Pepen

Staff Accountant

x

Johnny Pepen

Staff Accountant

Perkins, Stephen

Stephen Perkin

Senior Manager, QA Operations

x

Stephen Perkin

Senior Manager, QA Operations

Reyes, Armando

Armando Reyes

Director, Clinical Operations

x

Armando Reyes

Director, Clinical Operations

Searle, Stephen

Stephen A. Searle

Associate Director, Program Management

x

Stephen A. Searle

Associate Director, Program Management

Shen, Yuyi

Yuyi Shen, PhD

VP, Technical Operations

x

Yuyi Shen, PhD

VP, Technical Operations

Srinivasan, Usha

Usha Srinivasan

Vice President, Regulatory Affairs

x

Usha Srinivasan

Vice President, Regulatory Affairs

Sundaram, Sam

Sam Sundaram

Executive Assistant & Operations Manager

x

Sam Sundaram

Executive Assistant & Operations Manager

Tashi, Karma

Karma Tashi

Director, GMP Quality Drug Substance

x

Karma Tashi

Director, GMP Quality Drug Substance

Tubridy, Karen

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics.  Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.  She has had responsibility for driving global program strategies to IND,

 READ MORE

Karen Tubridy, PharmD

Chief Operating Officer

x

Karen Tubridy, PharmD

Chief Operating Officer

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics.  Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.  She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings.  In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen).  She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs.  Karen holds a BS in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.

Weems Gary

Garry Weems

VP, Clinical Science

x

Garry Weems

VP, Clinical Science

Wilkins, Jeffrey

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

 READ MORE

H. Jeffrey Wilkins, MD

Chief Medical Officer

x

H. Jeffrey Wilkins, MD

Chief Medical Officer

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.

Yates, Bill

Bill Yates

Vice President, Information Technology

x

Bill Yates

Vice President, Information Technology

Pruzanski, Mark

Mark Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences. Most recently he served as Chairman and Chief Executive Officer of Versanis Bio where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company’s acquisition in 2023 by Eli Lilly and

 READ MORE

Mark Pruzanski, MD

Chairman of the Board

x

Mark Pruzanski, MD

Chairman of the Board

Mark Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences. Most recently he served as Chairman and Chief Executive Officer of Versanis Bio where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company’s acquisition in 2023 by Eli Lilly and Company. Prior to joining Versanis, he founded and was the longstanding Chief Executive Officer of Intercept Pharmaceuticals (ICPT). At Intercept, he pioneered a novel regulatory and development strategy in chronic nonviral liver diseases that resulted in the successful global commercialization of the first-in-class FXR agonist obeticholic acid for the treatment of primary biliary cholangitis (PBC), marketed in more than 40 countries under the brand name OCALIVA™. He also led the effort to establish the regulatory, development and commercial basis for therapies targeting nonalcoholic steatohepatitis (NASH), which has become a leading reason for liver failure due to the global obesity epidemic. Mark is currently a member of the Board of Directors of several biotechnology companies, the Emerging Company Section of the Biotechnology Innovation Organization (BIO), and the Foundation for Defense of Democracies. Mark received his MD from McMaster University in Hamilton, Canada, a MA degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a BA degree from McGill University in Montreal, Canada.

Martin, Alex

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

 READ MORE

Alex Martin

Chief Executive Officer

x

Alex Martin

Chief Executive Officer

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

Boyce, Sarah

Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company’s successful Series C funding

 READ MORE

Sarah Boyce

President and Chief Executive Officer
Avidity Biosciences

x

Sarah Boyce

President and Chief Executive Officer
Avidity Biosciences

Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company's successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

Dybbs, Mike

Mike is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Mike was a partner at New Leaf Venture Partners. Before New Leaf Venture Partners Mike was a principal at the Boston Consulting Group, where he consulted for biotech and pharma clients. Mike currently serves on the

 READ MORE

Mike Dybbs, PhD

Partner, Samsara BioCapital

x

Mike Dybbs, PhD

Partner, Samsara BioCapital

Mike is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Mike was a partner at New Leaf Venture Partners. Before New Leaf Venture Partners Mike was a principal at the Boston Consulting Group, where he consulted for biotech and pharma clients. Mike currently serves on the boards of directors of Nkarta (NKTX), Sutro (STRO), and several private companies, including EnaraBio, Fluent Biosciences, Respira Therapeutics and Ionpath. Mike received an AB in biochemical sciences from Harvard College and a PhD in molecular biology from University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship.

Fang, Ming

Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead Sciences. He received a BA in Computer Science from

 READ MORE

Ming Fang

Managing Director, Redmile Group

x

Ming Fang

Managing Director, Redmile Group

Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead Sciences. He received a BA in Computer Science from UC Berkeley and an MBA in Finance and Healthcare Management from the Wharton School of Business.

Hafler, Jason P. , PhD

Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow,

 READ MORE

Jason P. Hafler, PhD

Managing Director, Sanofi Ventures

x

Jason P. Hafler, PhD

Managing Director, Sanofi Ventures

Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm.  Jason’s active investments include Abcuro, Amathus Therapeutics, Escient Pharmaceuticals, Expansion Therapeutics, Glycomine, Q32 Bio, ReCode Therapeutics, Rome Therapeutics and Navitor Pharmaceuticals. Jason graduated with honors from Bowdoin College and holds a PhD from the University of Cambridge.

Park, Michele

Michele Park joined NEA in 2021 as an investor on the Healthcare team focused on the biopharma space. Prior to NEA, Michele was an investor at Clarus Ventures (now Blackstone Life Sciences). Previously, she spent time in biotechnology research analyst roles at Credit Suisse and Piper Jaffray. Michele received her PhD in molecular biology from

 READ MORE

Michele Park, PhD

Partner, New Enterprise Associates

x

Michele Park, PhD

Partner, New Enterprise Associates

Michele Park joined NEA in 2021 as an investor on the Healthcare team focused on the biopharma space. Prior to NEA, Michele was an investor at Clarus Ventures (now Blackstone Life Sciences). Previously, she spent time in biotechnology research analyst roles at Credit Suisse and Piper Jaffray. Michele received her PhD in molecular biology from Weill Cornell Graduate School of Medical Sciences, and completed her dissertation at Memorial Sloan Kettering Cancer Center. She holds a BA in molecular biology from Princeton.

Shah, Rajeev

Rajeev Shah has been a Managing Partner at RA Capital Management since 2004. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms.  He previously worked as a

 READ MORE

Rajeev Shah

Managing Partner, RA Capital Management

x

Rajeev Shah

Managing Partner, RA Capital Management

Rajeev Shah has been a Managing Partner at RA Capital Management since 2004. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms.  He previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Rajeev is currently a member of the board of directors of the public companies Solid Biosciences, Black Diamond Therapeutics and Satsuma Pharmaceuticals, as well as of a number of private biotechnology companies. He holds a BA from Cornell University, where he majored in Chemistry.

Cashdan, Jonah

Jonah Cashdan joined Bain Capital Life Sciences in 2018. Prior to joining Bain Capital, he worked at J.P. Morgan in their healthcare investment banking group, evaluating and executing strategic alternatives including M&A and debt/equity financings for clients across the pharmaceutical, biotech and medtech sectors. Prior to joining J.P. Morgan, Jonah studied synaptic physiology and sensory system

 READ MORE

Jonah Cashdan

Observer
Principal, Bain Capital Life Sciences

x

Jonah Cashdan

Observer
Principal, Bain Capital Life Sciences

Jonah Cashdan joined Bain Capital Life Sciences in 2018. Prior to joining Bain Capital, he worked at J.P. Morgan in their healthcare investment banking group, evaluating and executing strategic alternatives including M&A and debt/equity financings for clients across the pharmaceutical, biotech and medtech sectors. Prior to joining J.P. Morgan, Jonah studied synaptic physiology and sensory system development in various labs at Georgetown University. He graduated summa cum laude from Georgetown University receiving a BS in Neurobiology.

Knowles, Julius (Jay)

Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by Juno Therapeutics.  Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President

 READ MORE

Julius (Jay) Knowles

Observer
Partner, Mass General Brigham Ventures

x

Julius (Jay) Knowles

Observer
Partner, Mass General Brigham Ventures

Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by Juno Therapeutics.  Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President of Novalar Pharmaceuticals, Vice President of Business Development at Novacea, and Director, R&D Planning at Vertex Pharmaceuticals. He represents Mass General Brigham Ventures on the boards of Apres Therapeutics, Keros Therapeutics, SwanBio Therapeutics, and Triplet Therapeutics. Jay earned his MBA in Finance from Wharton Business School, an MSc in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College.

NEA

Privacy Site Credits Terms of Use

© 2025 Abcuro